ArticleProbiotics and antimicrobial proteins2026
Hepatoprotective Mechanisms of Lactiplantibacillus plantarum SCS7 Cell-Free Extract Against Aflatoxin B1 Toxicity.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aflatoxin B1 (AFB1) is a widespread contaminant of food and feed that poses significant risks to both human and animal health. Developing safe and effective strategies to mitigate its toxicity remains a major public health priority. In this study, we investigated the protective effects of Lactiplantibacillus plantarum SCS7 cell-free extract (CFE) against AFB1-induced liver injury using integrated in vivo (mouse) and in vitro (AML12 hepatocyte) models. CFE treatment markedly alleviated AFB1-induced hepatic damage, mitochondrial dysfunction, and gut microbiota dysbiosis. Mechanistic analyses indicate that the protective effects of CFE are associated with the alleviation of excessive mitophagy and concomitant restoration of the PINK1/Parkin signaling axis, while systemic protection is conferred through modulation of the gut-liver axis. Importantly, unlike live probiotics, CFE circumvents concern related to intestinal colonization and biosafety while maintaining multi-pathway efficacy. Notably, this study identifies a previously unrecognized role for probiotic-derived metabolites in organelle quality control, demonstrating that CFE mitigates liver injury by inhibiting pathological mitophagy. Furthermore, CFE reshaped the intestinal microbiota and promoted the production of beneficial microbial metabolites, changes that were closely associated with improved hepatic homeostasis. Collectively, these findings suggest a coordinated interplay among the gut microbiota, microbial metabolites, and restoration of the PINK1/Parkin pathway, thereby providing a theoretical foundation for the development of stable, cell-free probiotic therapeutics with potential applications in food safety and public health.
Indexed as
Identifiers
42068434What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.